Rapamycin (Sirolimus)

Pfizer辉瑞授权 目录号:S1039 别名: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。

规格 价格 库存 购买数量  
RMB 2501.99 现货
RMB 580.39 现货
RMB 2216.87 现货
RMB 5501.68 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献82篇:

产品安全说明书

mTOR抑制剂选择性比较

生物活性

产品描述 Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。
靶点
mTOR [1]
(HEK293 cells)
~0.1 nM
体外研究

Rapamycin作用于HEK293细胞,抑制内源性mTOR活性,IC50为~0.1 nM,而iRap和AP21967 作用时,IC50分别为~5 nM 和~10 nM。[1] Rapamycin处理酿酒酵母,诱导细胞周期停在G1/S期,且抑制翻译。[2] Rapamycin显著抑制T98G和U87-MG细胞活力,这种作用具有剂量依赖性,IC50分别为2 nM和 1 μM, 而对U373-MG细胞没有作用活性,IC50>25 μM。Rapamycin(100 nM) 作用于对Rapamycin敏感的U87-MG和T98G细胞,通过抑制mTOR功能,而诱导细胞周期停在G1期,也诱导自噬而不是凋亡。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MYDDfZRwfG:6aXOgRZN{[Xl? MVOxNEBvVQ>? NV\VOmFJPzJiaB?= NELpRohFVVOR NX\zWZJmWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MnnYNlQ6ODB6N{O=
HT-29 M1PPemN6fG:2b4jpZ{BCe3OjeR?= NFrxUlIyOCCwTR?= MkjYO|IhcA>? Mn3mSG1UVw>? NFLQPWxRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= M1XlXVI1QTByOEez
HT-29 M1\TdGN6fG:2b4jpZ{BCe3OjeR?= M2PoTlExKG6P NXzGVHdxPzJiaB?= MUTEUXNQ MVTQc5RmdnSrYYTld{A2NW[udX;yc5Vz[WOrbD3pcoR2[2WmIHP5eI91d3irY3n0fS=> M{HDfVI1QTByOEez
PC3 M{\Le2tqdmG|ZTDBd5NigQ>? MkDENVAxKG6P NELDO5QyKGh? NFvJWm9FVVOR M4q0[nBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u NFvC[oEzOTl5OE[4Ny=>
PC3 NIDZOFJMcW6jc3WgRZN{[Xl? M{LDdVExOCCwTR?= NHfWO3gyKGh? MlrMSG1UVw>? MYnEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NXLreVl1OjF7N{i2PFM>
PC3 NXzme2xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\GcoMyNjVizszN M3;TVlEhcA>? NHHEfFBFVVOR NUW1e5Y4UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N NHHW[FYzOTl5OE[4Ny=>
HEK293 MUnGeY5kfGmxbjDBd5NigQ>? NHL1NWIyODBibl2= Mn7JPEBp Mm[3SG1UVw>? NIL6fFFKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= NGXHbFAzOTV|OUOwNS=>
BT-20 M2jMd2tqdmG|ZTDBd5NigQ>? MUWyNEDPxE1? MVvEUXNQ M4P3ZWRw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w M4TUSFIyOzV|NUWx
U937 MnrPRY51cWKjY4TldolidCCDc4PhfS=> NUf4WYFZPTBizszN MoLpOFghcA>? MVnEUXNQ MlTmTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| NGP5coEzOTF2MkGwOi=>
U937 NX[xTZdGSW62aXLhZ5RmemmjbDDBd5NigQ>? NVfJ[mZGPTBizszN MYe0PEBp NVLhUG5QTE2VTx?= MkHiSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? MX:yNVE1OjFyNh?=
U937 M{DneWFvfGmkYXP0[ZJq[WxiQYPzZZk> MmjZOVAh|ryP M2CxWlQ5KGh? M4HGSmROW09? NVWyW21wTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? Ml;CNlEyPDJzME[=
MCF-7 NGfLZ5dCfXSxcHjh[5khSXO|YYm= MYKzNEBvVQ>? MUm0JIg> NYHl[WZ3TE2VTx?= MlzJTY5lfWOnczDheZRweGijZ4m= Mk\xNlAxOjhzM{S=
U87MG NI\WW49McW6jc3WgRZN{[Xl? NF3mclcyKM7:TR?= MmCxOkBp NWnkc4NTTE2VTx?= NXewbGpJWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= M1zuW|E6QDR6NEC0
U87MG M{fKWWtqdmG|ZTDBd5NigQ>? NI\Cc2oyKM7:TR?= M4DjPVYhcA>? NH;lTlFFVVOR MW\Qc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= NInxU3UyQTh2OESwOC=>
U87MG M3u4dWtqdmG|ZTDBd5NigQ>? NGPWOWQyKM7:TR?= M1LNXVYhcA>? MlzrSG1UVw>? M4HXSGRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w M4e1N|E6QDR6NEC0
U87MG NWi1colrU2mwYYPlJGF{e2G7 M{W3PVEh|ryP M1;zZVYhcA>? MYXEUXNQ MV7Ec4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NWTaTGljOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb MorjRZV1d3CqYXf5JGF{e2G7 NWDDW3M3OC5{IN88US=> MXOyOEBp MU\EUXNQ MV7JcoR2[2W|IHH1eI9xcGGpeR?= NXn2PGMxOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NILWbVJCfXSxcHjh[5khSXO|YYm= M3nwS|AvOiEQvF2= MYSyOEBp NW\ZbpRUTE2VTx?= NH3NenJKdmS3Y3XzJIF2fG:yaHHnfS=> MnXONVg{QTF7NEm=
H4 NIThbGVHfW6ldHnvckBCe3OjeR?= M1;xTlAvOiEQvF2= NFHlfnUzPCCq M37FZ2ROW09? MnvRTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> NED2fngyQDB{NEW4OC=>
HeLa NIfEb3lHfW6ldHnvckBCe3OjeR?= MWOxNFAhdk1? NFP1fIo{PiCq NWTZcZYzTE2VTx?= M2iwe2lv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NUG2NVJNOTd3NkOzPFU>
HeLa NHvsfFVHfW6ldHnvckBCe3OjeR?= M4P1dVExOCCwTR?= M1XyUlM3KGh? MoSxSG1UVw>? MmLwTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MYKxO|U3OzN6NR?=
HeLa M1;aNWZ2dmO2aX;uJGF{e2G7 M1XpTFExOCCwTR?= MmPBN|YhcA>? M1u2UmROW09? NF3HUoxKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NY\pRZVXOTd3NkOzPFU>
SYF MVnGeY5kfGmxbjDBd5NigQ>? NX\hUVdpOTByIH7N NYXXe2lnOjRiaB?= NUDkNnR5TE2VTx?= MkHGTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u MXKxO|U3OzN6NR?=
SYF MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2xNFAhdk1? MkjLNlQhcA>? MnvxSG1UVw>? MknoTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= NEPvWlMyPzV4M{O4OS=>
HEK293T MoXiRY51cX[rcnHsJGF{e2G7 NG\1V|kyKG6P MoTpOEBl M1HHb2ROW09? MUXJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= MWOxO|Q5PTVyMR?=
HEK293T NEXT[49CdnSrdnnyZYwhSXO|YYm= M1fsU|Ehdk1? MmW0OEBl NETRR4tFVVOR MoL1TY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= MUSxO|Q5PTVyMR?=
PBMC M{fEb2Z2dmO2aX;uJGF{e2G7 NFn1eWsyKG6P M1HRbVE1KGR? M4f4bWROW09? NH;CTXdT\WS3Y3XzJGNEWjViZHXud4l1gQ>? NV\CeWNiOTd2OEW1NFE>
PBMC MVXGeY5kfGmxbjDBd5NigQ>? MYixJI5O NYLsfopkOTRiZB?= MWLEUXNQ MnfHSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> NEXDOFYyPzR6NUWwNS=>
HEK293 cells MXPLbY5ie2ViQYPzZZk> NELlToE2OCCwTR?= NULhbGhCPDVibXnu Ml71SG1UVw>? NWO1Zpp2UW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?= NU\QfFVEOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MVTGeY5kfGmxbjDBd5NigQ>? NF35WHoyODBibl2= MknwOEBp M3LPWGROW09? M2L6dmlv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk MYGxO|EzQDJ4Mh?=
Human mixed lymphocyte MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTvOUBvVQ>? MULEUXNQ MXHJR|UxRTFwNjDuUU4> MXOxOlE5PTh4NR?=
Lewis rat lymph node cells M3LkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[1JO69VQ>? MljhSG1UVw>? M2L2W2lEPTB;Mj62JO69VQ>? M{HKU|E3OTh3OE[1
cells from the thymus of normal BALB/c mice Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn0VGtrOTBibl2= NVzzUlFuPzJiaB?= NW\CdnU5TE2VTx?= NVjJVmhiUW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=> NIj0SYsyODB{MUm0PC=>
MRK-nu-1 M3O1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jxdWlEPTB;MD64OFUheE1? NVHsRXJuW0GQR1XS
OCUB-M NILHRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTVwMkSgdG0> MUHTRW5ITVJ?
SF539 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;WTmFMUUN3ME2xNU43KHCP NVj2UZdIW0GQR1XS
ES4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSw[lFKSzVyPUKxMlUheE1? MX\TRW5ITVJ?
RL95-2 NF;D[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXnNmY{UUN3ME2xNFcheE1? MVHTRW5ITVJ?
LC-2-ad MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTHTIJKSzVyPUSyN{BxVQ>? Mo\LV2FPT0WU
Daudi NFzKc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rCNWlEPTB;NEO0JJBO MWHTRW5ITVJ?
NTERA-S-cl-D1 Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT0TXp1UUN3ME20OFMheE1? M3LVeXNCVkeHUh?=
OS-RC-2 NI\ZOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTZ3MjDwUS=> NX;yVlZCW0GQR1XS
VA-ES-BJ M2HOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\rbYh3UUN3ME23NlMheE1? MWPTRW5ITVJ?
GR-ST NFXKbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTh2NjDwUS=> MWLTRW5ITVJ?
SW872 NGjKdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO0TYJGUUN3ME24OFYheE1? NXLUWJpTW0GQR1XS
NOS-1 NHHJdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjRPGZKSzVyPUi3NUBxVQ>? NUHa[4xoW0GQR1XS
MC116 NGDQe|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z5WWlEPTB;OUi1JJBO MkDyV2FPT0WU
NCI-H1355 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjvRpo5UUN3ME2xMlAyKG6P MkjHV2FPT0WU
RPMI-8226 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC3UY5ZUUN3ME2xMlE6KG6P MXjTRW5ITVJ?
TE-15 NGLhXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv4TWM2OD1zLkO2JI5O NV25W4VFW0GQR1XS
Ramos-2G6-4C10 MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne3TWM2OD1zLkS2JI5O M1zwNXNCVkeHUh?=
KU812 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmybWp6UUN3ME2yMlAyKG6P M3XtSnNCVkeHUh?=
EW-1 NIjDVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH25[XNKSzVyPUKuNVchdk1? M4jkeXNCVkeHUh?=
KS-1 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlriTWM2OD1{LkS1JI5O MWLTRW5ITVJ?
SK-LMS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG3bnN5UUN3ME2yMlQ6KG6P M4HjUnNCVkeHUh?=
TGBC1TKB MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH32S4hKSzVyPUKuOlkhdk1? MUfTRW5ITVJ?
TE-6 NGDS[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK5N5BKSzVyPUKuO|chdk1? NWS5RVRRW0GQR1XS
ETK-1 NY[wVYxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwOEKgcm0> MYDTRW5ITVJ?
BE-13 M{XZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\DTWM2OD1{Lkm5JI5O NWiyNJI2W0GQR1XS
A3-KAW MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\zTWM2OD1{Lkm5JI5O MYXTRW5ITVJ?
TE-10 NHK3dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki1TWM2OD1|LkOgcm0> MVHTRW5ITVJ?
DOHH-2 MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\jTWM2OD1|LkO1JI5O MorIV2FPT0WU
ES6 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTNwNEOgcm0> M4r1SnNCVkeHUh?=
OPM-2 M4TrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv0WIRKSzVyPUSuNVUhdk1? NHnRS3hUSU6JRWK=
SH-4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTRwM{Sgcm0> NIT1RY5USU6JRWK=
NB13 M1z3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfrPYpZUUN3ME20MlM3KG6P M1vIfnNCVkeHUh?=
HUTU-80 NXH4UIE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjUTWM2OD12LkSyJI5O NF7wZVVUSU6JRWK=
CCRF-CEM NVW2Um5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPwNldbUUN3ME20Mlk1KG6P NGjXWWlUSU6JRWK=
TGBC24TKB NW[2ZYl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTVwNUGgcm0> NXjhUYNSW0GQR1XS
697 NE\jSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jLOmlEPTB;Nj6yPEBvVQ>? NFzNWmtUSU6JRWK=
J-RT3-T3-5 NI\1eZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfMdFNKSzVyPU[uOFYhdk1? M4fUbXNCVkeHUh?=
KALS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTZwNU[gcm0> NGHqcG5USU6JRWK=
no-10 NHjzS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vIXGlEPTB;Nz6yPUBvVQ>? Ml;QV2FPT0WU
SK-NEP-1 NWW2dpl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvxNldKSzVyPUiuO|khdk1? MYjTRW5ITVJ?
L-540 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDxXWlRUUN3ME2xNE41OiCwTR?= NELEWnFUSU6JRWK=
JiyoyeP-2003 Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXq[XBvUUN3ME2xNE46PCCwTR?= MoPYV2FPT0WU
HH M33hNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vMU2lEPTB;MUGuN|khdk1? M17sNHNCVkeHUh?=
SR NUTEcY46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTwPZhzUUN3ME2xNU41PSCwTR?= M3;PWHNCVkeHUh?=
QIMR-WIL NXixPWE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr4b3FKSzVyPUGxMlg2KG6P M1\SN3NCVkeHUh?=
A4-Fuk M4HZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvKTWM2OD1zMz6xNkBvVQ>? MV;TRW5ITVJ?
CESS NXjG[HFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfWTWM2OD1zMz6xN{BvVQ>? NWjITJM{W0GQR1XS
KE-37 MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTE[WtSUUN3ME2xOk4xPyCwTR?= NFG2d|ZUSU6JRWK=
SK-UT-1 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy1U5pKSzVyPUG2MlgyKG6P MYXTRW5ITVJ?
SIG-M5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Dt[2lEPTB;MUeuNlUhdk1? Mn7mV2FPT0WU
HT NV3ONIVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF5Lk[gcm0> NGnhcoRUSU6JRWK=
DEL NH3JcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLRXZRTUUN3ME2xO{46QSCwTR?= MV;TRW5ITVJ?
SK-PN-DW NIO3O|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vL[mlEPTB;MkCuNlMhdk1? MmLQV2FPT0WU
RPMI-8402 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[4SGlEPTB;MkGuO|chdk1? NVnGV3BtW0GQR1XS
RPMI-6666 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;tbZRFUUN3ME2yOE41OiCwTR?= NW\uWWNCW0GQR1XS
NCI-H720 M1zZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu3[2JkUUN3ME2yOU41OSCwTR?= Ml;xV2FPT0WU
EW-16 NV7SVVVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\COnFKSzVyPUK2Mlg4KG6P MUHTRW5ITVJ?
BL-70 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljQTWM2OD1{OD6zPEBvVQ>? Ml;uV2FPT0WU
SF126 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTOTWM2OD1|MD6zPEBvVQ>? MnzUV2FPT0WU
BC-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF2w[HlKSzVyPUOxMlI3KG6P MkjQV2FPT0WU
MHH-PREB-1 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfme2plUUN3ME2zNk41PCCwTR?= MYXTRW5ITVJ?
A101D M4DsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXzRmZKSzVyPUOyMlYzKG6P M33JcHNCVkeHUh?=
NMC-G1 NF7NWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPlbnBKSzVyPUOzMlY4KG6P NEHTVHZUSU6JRWK=
LB1047-RCC NG\oSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTN2Lk[5JI5O MnnOV2FPT0WU
EM-2 NETU[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULuUYgzUUN3ME2zPE42OyCwTR?= MnzRV2FPT0WU
COLO-684 NYHMUphoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u2fWlEPTB;M{muPEBvVQ>? NVXDR21wW0GQR1XS
Becker MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G3eGlEPTB;NEGuNFUhdk1? MXPTRW5ITVJ?
BL-41 NET3SG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnpTnVLUUN3ME20N{43PiCwTR?= MX\TRW5ITVJ?
MDA-MB-134-VI NHfj[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPTTWM2OD12ND6wNkBvVQ>? MmjxV2FPT0WU
L-363 M4r3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X3UmlEPTB;NESuO|Mhdk1? MmPQV2FPT0WU
ECC4 M4fTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;YeGlEPTB;NESuO|ghdk1? M3XVWHNCVkeHUh?=
A388 NFjQNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn3XmdKSzVyPUS0MlgzKG6P NInGbGxUSU6JRWK=
HEL MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLtOHhKSzVyPUS5Mlc6KG6P NX7rZ4pQW0GQR1XS
RKO M2\Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXBUHJyUUN3ME21NE4zQSCwTR?= MYTTRW5ITVJ?
KINGS-1 NXnodVBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTVzLkW1JI5O NWniZoZHW0GQR1XS
EB-3 NVrofWZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPiT2tFUUN3ME21Nk43PyCwTR?= NF;6VWVUSU6JRWK=
ARH-77 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\iTWM2OD13Mj64JI5O M2XpZXNCVkeHUh?=
GCIY M3n1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XZW2lEPTB;NUOuOFYhdk1? NW\pOFFjW0GQR1XS
NCI-H1304 NIjibVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PGN2lEPTB;NUeuNlIhdk1? NUnJXZZNW0GQR1XS
KARPAS-299 NWTPOGV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;wPXlCUUN3ME22NU45OiCwTR?= MoDKV2FPT0WU
IA-LM M1;ZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36yUGlEPTB;NkiuNVMhdk1? NXS3fJVuW0GQR1XS
GI-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf5blVKSzVyPUewMlM6KG6P MlvWV2FPT0WU
TE-11 NWPO[pd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTd5LkG3JI5O M{HVdHNCVkeHUh?=
LS-411N M1TFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXMcJdKSzVyPUe3MlU4KG6P NIrZ[mVUSU6JRWK=
no-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XuU2lEPTB;OEOuNlQhdk1? M2DNZXNCVkeHUh?=
MV-4-11 NYLBZocyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTh|LkezJI5O Mnf3V2FPT0WU
BV-173 NVHjbmtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HTXmlEPTB;OEOuPVchdk1? MXnTRW5ITVJ?
CMK NF\YRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TmSWlEPTB;OESuNVYhdk1? NE\jOJpUSU6JRWK=
LC4-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTMTWM2OD16Nj63NkBvVQ>? MXrTRW5ITVJ?
COR-L279 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTSTWM2OD16Nz6yOUBvVQ>? MkfkV2FPT0WU
NCI-H209 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTh5LkSxJI5O NWO2RYJIW0GQR1XS
Raji MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X3ZWlEPTB;OEmuO|Ihdk1? Mn\KV2FPT0WU
LB996-RCC Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy4R5NbUUN3ME25N{41OyCwTR?= MmrhV2FPT0WU
NCI-H526 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTl|LkW5JI5O M1rSTnNCVkeHUh?=
KGN M2fqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO0cJk5UUN3ME25Ok4zQSCwTR?= M3vDNHNCVkeHUh?=
MOLT-4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm2TWM2OD17Nj63PUBvVQ>? NV;5UlFDW0GQR1XS
PF-382 NWDJc4ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\5OGlEPTB;OU[uO|khdk1? NILiZZJUSU6JRWK=
BC-3 MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKyS5RKSzVyPUm5MlE5KG6P NYf3b45qW0GQR1XS
KARPAS-422 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG4OI1RUUN3ME2xNFIvODlibl2= MXrTRW5ITVJ?
SBC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFyNz63OUBvVQ>? NWLhNZFGW0GQR1XS
LC-1F NFWzUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17FXmlEPTB;MUC4MlA2KG6P M{nMbnNCVkeHUh?=
GB-1 NHnX[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr6TWM2OD1zMEmuNFIhdk1? NUXNZWw{W0GQR1XS
SNB75 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTzdHFKSzVyPUGxPU43QSCwTR?= NILiUppUSU6JRWK=
BB65-RCC NGK0[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfPTWM2OD1zMUmuPVMhdk1? NIDMXVZUSU6JRWK=
NCI-N87 NIHMZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TKZWlEPTB;MUKxMlk5KG6P NW\4Z4dPW0GQR1XS
IST-MEL1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi3RYdTUUN3ME2xNlIvOzhibl2= NEmzPGZUSU6JRWK=
HOP-62 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vTWWlEPTB;MUK2Mlg6KG6P NUfwfHFSW0GQR1XS
ACN NVPJ[oRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;JeIVKSzVyPUG0Ok44PSCwTR?= NI\Q[lFUSU6JRWK=
DMS-114 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDHflBKSzVyPUG1NE43PyCwTR?= M{XmZ3NCVkeHUh?=
MLMA NHTzWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PqbWlEPTB;MUW5Mlg5KG6P NVH6TZVjW0GQR1XS
HT-144 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPaTWM2OD1zNkWuOFMhdk1? MnHFV2FPT0WU
C2BBe1 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHrTWM2OD1zNkeuO|Yhdk1? M1jyS3NCVkeHUh?=
L-428 NGnhWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3ZfmtzUUN3ME2xO|cvPyCwTR?= M4HDW3NCVkeHUh?=
DU-4475 NUDPPIVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37aZWlEPTB;MUi3MlY5KG6P MWLTRW5ITVJ?
CP67-MEL MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr1TWM2OD1zOUmuN|ghdk1? NVPtWlR4W0GQR1XS
MEG-01 NIHMT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLRTWM2OD1{MEGuPVYhdk1? NVH1d4tFW0GQR1XS
IST-SL2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;yS4dKSzVyPUKwPE43OyCwTR?= NIPy[|RUSU6JRWK=
ES8 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Hae2lEPTB;MkK1Mlk1KG6P NXLGfZpqW0GQR1XS
COLO-800 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJ|NT6yPEBvVQ>? M16ye3NCVkeHUh?=
MFH-ino NUSzOWNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG2OmdLUUN3ME2yN|UvQDRibl2= NUDOU4FvW0GQR1XS
OVCAR-4 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHETWM2OD1{M{euNlQhdk1? NX7GfnNCW0GQR1XS
PSN1 NYnGT5B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPKTWM2OD1{NEKuO|Ehdk1? Mon6V2FPT0WU
EW-12 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknCTWM2OD1{NEOuNUBvVQ>? MXzTRW5ITVJ?
HCC1599 NGPafnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn76TWM2OD1{NkGuOFchdk1? NUn3WY41W0GQR1XS
SJSA-1 NWHkTYk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f1TGlEPTB;MkexMlQ3KG6P NV\x[Xc6W0GQR1XS
ST486 NHvoenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ7Nj6xOEBvVQ>? MlfCV2FPT0WU
NOMO-1 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTRTWM2OD1|MECuNlEhdk1? M{[2bHNCVkeHUh?=
MN-60 NVf1bHBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDuTWM2OD1|MEWuN|Ihdk1? NFHhR45USU6JRWK=
HCC1187 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXxWoNYUUN3ME2zNFcvOjVibl2= NFztSIpUSU6JRWK=
SW982 M2f3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLMTWM2OD1|MUSuO|Uhdk1? NUKyNoo{W0GQR1XS
LB647-SCLC NIXBPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;3TWM2OD1|MkiuO|Ehdk1? NXGxO3hpW0GQR1XS
HC-1 M2LVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfX[mdKSzVyPUOzOU42KG6P NX\Ub5BOW0GQR1XS
EHEB NXTBNVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfhNoFKSzVyPUOzO{42OiCwTR?= MkHYV2FPT0WU
TUR M3;2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MornTWM2OD1|NkOuPVUhdk1? NYCyN|BoW0GQR1XS
LU-139 NXrwUpd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rhWGlEPTB;M{e4MlAzKG6P MXvTRW5ITVJ?
NB1 M4LPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTKTWM2OD1|OESuOFUhdk1? MmDhV2FPT0WU
BB30-HNC NETadlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7nNIVKSzVyPUO4PE4{OiCwTR?= Ml7XV2FPT0WU
HAL-01 MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfXRoNKSzVyPUO4PU4zPiCwTR?= Mor5V2FPT0WU
K5 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHzR|VKSzVyPUSxNU4{PyCwTR?= NXHXV5hIW0GQR1XS
MZ2-MEL NHnyZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvOWG9[UUN3ME20NVMvPjRibl2= MWXTRW5ITVJ?
RXF393 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPiTWM2OD12MU[uOFUhdk1? MorBV2FPT0WU
NCI-H1648 NV;UNHhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRzNz61N{BvVQ>? MkHpV2FPT0WU
TE-12 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PG[WlEPTB;NEO0MlI3KG6P NHTicmlUSU6JRWK=
EoL-1- MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nGS2lEPTB;NEO3Mlk5KG6P MU\TRW5ITVJ?
JAR NFrad|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nMTGlEPTB;NEO4MlYzKG6P NITTdFBUSU6JRWK=
DSH1 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO3[5VKSzVyPUS1PE46OSCwTR?= MnXOV2FPT0WU
NCI-H187 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7MZZlKSzVyPUS2Nk45OSCwTR?= NXXDeHBJW0GQR1XS
HCE-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTR5Nz62OkBvVQ>? M2fOXXNCVkeHUh?=
8-MG-BA NIf3cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnqTWM2OD13OEGuOVIhdk1? NH;PRZlUSU6JRWK=
KLE NXW5epgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTV6NT6yJI5O MYrTRW5ITVJ?
KNS-42 NWTQc|hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTV6Nj64NUBvVQ>? NGHt[VVUSU6JRWK=
MSTO-211H M{Xi[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fWNWlEPTB;NkC5Mlc1KG6P NXTyeIlYW0GQR1XS
GDM-1 NWjZ[W9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;reG1KSzVyPU[xOE4xQSCwTR?= MUfTRW5ITVJ?
TE-1 M3H6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLwUIpKSzVyPU[0Ok4yOiCwTR?= MkHXV2FPT0WU
BT-474 M{P5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorOTWM2OD14NEeuNFYhdk1? MkTKV2FPT0WU
KARPAS-45 M4LoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nSVmlEPTB;NkS3MlYhdk1? NYLJXlJiW0GQR1XS
MOLT-16 M3\KXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTZ2Nz65N{BvVQ>? MnXlV2FPT0WU
KURAMOCHI MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrSTWM2OD14NUeuOVEhdk1? Mmi3V2FPT0WU
K-562 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInFUopKSzVyPU[2PU42OSCwTR?= M33mOnNCVkeHUh?=
EKVX M{\GNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTZ5Mj63NUBvVQ>? MYjTRW5ITVJ?
GAK Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXWTWM2OD14N{WuN{BvVQ>? MU\TRW5ITVJ?
NCI-SNU-5 Mlq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP6e3hnUUN3ME22PVAvODFibl2= NITT[2dUSU6JRWK=
NCI-H2126 NEjw[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTd{Nj64O{BvVQ>? NHz1[mNUSU6JRWK=
CTV-1 NETBfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXITWM2OD15NESuPUBvVQ>? MVLTRW5ITVJ?
SW962 M3S0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTd2OD60OEBvVQ>? MoPsV2FPT0WU
MONO-MAC-6 NGDqcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPiPIM6UUN3ME23OVYvQTNibl2= MnTYV2FPT0WU
NCI-H748 M33sOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HWbGlEPTB;N{W4Mlk6KG6P NUTSUpE5W0GQR1XS
NCI-H524 NEPvZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTd6MD63N{BvVQ>? NVnadIFFW0GQR1XS
LS-123 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvuTWM2OD15OUWuOlkhdk1? M17ZNXNCVkeHUh?=
NB7 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zHb2lEPTB;OEG0MlE1KG6P M2nZfXNCVkeHUh?=
LS-1034 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLYTWM2OD16MkiuPVghdk1? NGe0SHFUSU6JRWK=
TE-5 NVXzT5hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojUTWM2OD16OEOuOVYhdk1? M2XWfXNCVkeHUh?=
A704 M4raSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\XTnBKUUN3ME24PVkvOTVibl2= M3LGfHNCVkeHUh?=
TK10 NEHYZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W1b2lEPTB;OUG2MlA{KG6P MYLTRW5ITVJ?
NCI-H345 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXsTWM2OD17NEOuNlIhdk1? NUL4[opnW0GQR1XS
CGTH-W-1 M4\XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTl2OD6xN{BvVQ>? NWHacpJ5W0GQR1XS
NCI-H510A M{\KSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P2T2lEPTB;OUi1MlEzKG6P MX3TRW5ITVJ?
NCI-H1963 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;xSGlEPTB;MT6wN|I6OiEQvF2= NFXsTlRUSU6JRWK=
SCC-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nucGlEPTB;MT6wN|QyPCEQvF2= MmHvV2FPT0WU
EW-11 NHrRZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\BTWM2OD1zLkC4O|Q{KM7:TR?= MY\TRW5ITVJ?
CPC-N MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\oeVdKSzVyPUGuNFg5KM7:TR?= NU\QRYp2W0GQR1XS
NCI-H1417 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnweHZDUUN3ME2xMlEzOjZizszN NGX5c3JUSU6JRWK=
DG-75 NWexPINNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwMU[yPFUh|ryP MlXQV2FPT0WU
HD-MY-Z MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DCXmlEPTB;MT6xOlQyPiEQvF2= Ml\UV2FPT0WU
ATN-1 M33HWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHtTWM2OD1zLkK2NlA6KM7:TR?= MnfLV2FPT0WU
KM-H2 M3exW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwMk[0NFgh|ryP Mkj1V2FPT0WU
NCI-H2081 NVLJe|F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjyTWM2OD1zLkK2OlM4KM7:TR?= NIr4VmNUSU6JRWK=
HL-60 NIDPV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrMZYI5UUN3ME2xMlI3QTV7IN88US=> NWTUSppkW0GQR1XS
DB M{jBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DxZ2lEPTB;MT6yO|I1OiEQvF2= MVzTRW5ITVJ?
NCI-H1522 MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfUT4lKUUN3ME2xMlI5QDh5IN88US=> Mm\wV2FPT0WU
AM-38 NVTTZ2tKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVntPZRSUUN3ME2xMlMxPzJizszN MnjTV2FPT0WU
NCI-H446 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TQcmlEPTB;MT6zNlEzOSEQvF2= MkOyV2FPT0WU
SU-DHL-1 NIrCSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn0dpFlUUN3ME2xMlMzQDBzIN88US=> M3LtUXNCVkeHUh?=
NH-12 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHSdVRrUUN3ME2xMlM3Ozd2IN88US=> NFjk[5lUSU6JRWK=
DMS-79 NXTuZ5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFwM{[4OlYh|ryP MV3TRW5ITVJ?
NCI-H716 M{\VTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HYTWlEPTB;MT6zPFk5PiEQvF2= NH7aWGZUSU6JRWK=
ML-2 NX;ueohJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HJc2lEPTB;MT60NVUzQSEQvF2= NFvUTGtUSU6JRWK=
NB10 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\iSpdKUUN3ME2xMlQ3PjN{IN88US=> M2TLfHNCVkeHUh?=
ONS-76 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwNUO1Olkh|ryP NYPPUJdkW0GQR1XS
LOUCY NYXkS3R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFwNUS2OVch|ryP MnTPV2FPT0WU
SCLC-21H NV\h[WlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm4RmtKSzVyPUGuOVg2QDJizszN MYrTRW5ITVJ?
TGW M{TL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwNkO5O|Uh|ryP NH\iRndUSU6JRWK=
LXF-289 M{fFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnTR212UUN3ME2xMlc{OjZ6IN88US=> Mmn5V2FPT0WU
BB49-HNC Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PxdWlEPTB;MT63N|U5PiEQvF2= NVTQdmNoW0GQR1XS
NCI-H747 NW\kR2ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTrTHJGUUN3ME2xMlc2OzR4IN88US=> NFr3OI5USU6JRWK=
LU-165 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;NeJRjUUN3ME2xMlg1QTh4IN88US=> NFXBdFdUSU6JRWK=
OMC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFwOUWwOlYh|ryP NX7qcVhHW0GQR1XS
RCC10RGB MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PweGlEPTB;MT65OVgyPyEQvF2= NFnwd5lUSU6JRWK=
SW684 M{LQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwOU[wPVkh|ryP NF7kfpdUSU6JRWK=
TE-8 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL3NZZ1UUN3ME2yMlA2PTV7IN88US=> NEfqZlVUSU6JRWK=
SK-N-DZ NUjDfWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfGOGNDUUN3ME2yMlE{Ojd2IN88US=> NY\oblBCW0GQR1XS
EVSA-T NXLZVnFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDZTWM2OD1{LkG3N|E2KM7:TR?= M2\4XnNCVkeHUh?=
KASUMI-1 M1Kzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfLdFdJUUN3ME2yMlE5QDF3IN88US=> NFvLRmNUSU6JRWK=
NKM-1 M2jVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHkb|hJUUN3ME2yMlI2PDd{IN88US=> NIi0eWdUSU6JRWK=
CAL-148 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[zTWM2OD1{LkOzOlE1KM7:TR?= Mkn6V2FPT0WU
NCI-H64 NVfR[WtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn1dndnUUN3ME2yMlM1OjN{IN88US=> MoWzV2FPT0WU
KNS-81-FD MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXQZYJnUUN3ME2yMlM3PjJizszN MW\TRW5ITVJ?
KM12 M2Hj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJwNEC4N|kh|ryP MYXTRW5ITVJ?
SW954 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T1b2lEPTB;Mj60O|c4QSEQvF2= NWDWenVWW0GQR1XS
NCI-H1395 NWrjUZVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXLcGRZUUN3ME2yMlUzPjR3IN88US=> M1nnO3NCVkeHUh?=
DJM-1 NVL1bGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG0[3hKSzVyPUKuOlA3OyEQvF2= NWDzUmdiW0GQR1XS
COLO-668 M17ORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PuPGlEPTB;Mj64NlY6PSEQvF2= NIG5UZpUSU6JRWK=
NCI-H1436 MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHScHNbUUN3ME2yMlg2PjF3IN88US=> MlTkV2FPT0WU
LB2241-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDHTWM2OD1{Lki2PFM6KM7:TR?= NIflNpZUSU6JRWK=
GT3TKB NHnvNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz3TWM2OD1{Lki5NFU2KM7:TR?= MX3TRW5ITVJ?
COLO-824 NFXLOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jm[WlEPTB;Mj64PVc3QCEQvF2= NUnvemZ2W0GQR1XS
ES1 NVztdYlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJwOEm4O|kh|ryP MV;TRW5ITVJ?
LB771-HNC M2O5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorrTWM2OD1{LkmwPVQ3KM7:TR?= MnWyV2FPT0WU
GI-ME-N MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrvTWM2OD1|LkCwPVA1KM7:TR?= MnTpV2FPT0WU
NALM-6 NIL5TYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPJTWM2OD1|LkCwPVM{KM7:TR?= NYjkcJZqW0GQR1XS
LU-134-A M2\4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfhTWM2OD1|LkC1OFI2KM7:TR?= M3m2eXNCVkeHUh?=
DMS-153 NInBUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmSzTWM2OD1|LkC1PFI1KM7:TR?= NIXTPJBUSU6JRWK=
MZ1-PC MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\YWo5SUUN3ME2zMlA6ODd6IN88US=> M375N3NCVkeHUh?=
NCI-H1155 M37mOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm0PXBKSzVyPUOuNVE3OSEQvF2= M1HqSnNCVkeHUh?=
CAS-1 MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfmTWM2OD1|LkGzO|A4KM7:TR?= MmLDV2FPT0WU
D-502MG M2W4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLTTWM2OD1|LkG0N|kh|ryP MYDTRW5ITVJ?
NCI-H2141 M2PwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nGfGlEPTB;Mz6xO|Q2OiEQvF2= MkX3V2FPT0WU
NB6 NXX0fmt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHHTWM2OD1|LkG4NlU6KM7:TR?= NH;YPZdUSU6JRWK=
NCCIT M4LJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LlR2lEPTB;Mz6yNVgxQSEQvF2= MoLJV2FPT0WU
NB69 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwM{G4PVEh|ryP NEP5[W1USU6JRWK=
JVM-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHQTWM2OD1|LkO2OFM{KM7:TR?= MV\TRW5ITVJ?
K052 NHG3THFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nUWWlEPTB;Mz6zO|k3QCEQvF2= M333eXNCVkeHUh?=
HCC2157 M374SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDZTWM2OD1|LkWzNlI5KM7:TR?= NUTzTGxGW0GQR1XS
KMOE-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofpTWM2OD1|LkW0NlQzKM7:TR?= NXvZT3hwW0GQR1XS
SF268 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzu[mNKSzVyPUOuO|E2PTRizszN MUfTRW5ITVJ?
CHP-126 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zDe2lEPTB;Mz63OlQ2QCEQvF2= MULTRW5ITVJ?
CP66-MEL M1X2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PjeGlEPTB;Mz63PVA6PCEQvF2= M3W2ZnNCVkeHUh?=
NCI-H69 NWjvN2p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwMEG5N|Yh|ryP M3Tre3NCVkeHUh?=
A253 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTje3NwUUN3ME20MlAzOTBzIN88US=> NF:wSHhUSU6JRWK=
NB14 M4fBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTRwMUC0O|kh|ryP NIiwPWpUSU6JRWK=
NCI-H1694 NHnHZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTRwMUOxNVIh|ryP MkLwV2FPT0WU
NCI-H2196 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTRwMUexOlkh|ryP NXGzbpBUW0GQR1XS
TE-9 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;0[JNKSzVyPUSuNVc2QDJizszN NFfpeVJUSU6JRWK=
D-283MED MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPWVXZKSzVyPUSuNVg5PCEQvF2= M1HGWHNCVkeHUh?=
OCI-AML2 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHK[m9KSzVyPUSuNVk1QDlizszN MlP6V2FPT0WU
D-263MG NFHkZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvyUYhKSzVyPUSuNlI6PjFizszN MUjTRW5ITVJ?
MPP-89 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESyUllKSzVyPUSuNlc{ODRizszN MU\TRW5ITVJ?
LAMA-84 NUTVNXUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXzR4RKSzVyPUSuN|A1OjFizszN NHPzXW9USU6JRWK=
LB373-MEL-D M4fUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTRwM{[3PFkh|ryP MlrQV2FPT0WU
UACC-257 NIW2Z2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\JWphyUUN3ME20MlM6PTN2IN88US=> MnvoV2FPT0WU
MC-CAR M1vEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFqwUFlKSzVyPUSuOFM6QSEQvF2= M1XodHNCVkeHUh?=
COLO-320-HSR M2DldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnOe5FKSzVyPUSuOFQ1OjdizszN Mlq5V2FPT0WU
P30-OHK NUC2eZRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\Qb2lEPTB;ND62OlU5OSEQvF2= NWfLeZpoW0GQR1XS
UACC-812 NXfk[VJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Pi[WlEPTB;ND62PVE3OSEQvF2= M4nSb3NCVkeHUh?=
CTB-1 NUfHWVlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jPSWlEPTB;ND63NVU2PSEQvF2= NF:1PWJUSU6JRWK=
ALL-PO NIXBbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z2N2lEPTB;ND64OFA4PyEQvF2= NFriOWhUSU6JRWK=
SK-MEL-2 MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHmTWdKSzVyPUSuPFY6PTVizszN M1LIUXNCVkeHUh?=
TC-YIK NGnr[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKwbZBHUUN3ME20Mlk4QTR{IN88US=> MnzKV2FPT0WU
NCI-H1882 NVfPZ5NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17DRWlEPTB;NT6wNlAxOSEQvF2= M13uSHNCVkeHUh?=
MHH-CALL-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW0TWM2OD13LkC1NFQzKM7:TR?= NULxZWxiW0GQR1XS
U-87-MG MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTVwMEm0OlYh|ryP M4ThSnNCVkeHUh?=
NCI-H1092 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;4TWM2OD13LkK2OVU2KM7:TR?= MonzV2FPT0WU
TE-441-T NV6yNWZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHJWoZsUUN3ME21MlI4QDJizszN NYPS[npCW0GQR1XS
SK-MEL-1 M1nYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrkXYZ3UUN3ME21MlI6ODR2IN88US=> NYXYcotGW0GQR1XS
EW-22 Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTVwMkm0OlYh|ryP MV;TRW5ITVJ?
MZ7-mel MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnFNG5EUUN3ME21MlQxPjlzIN88US=> M{PncXNCVkeHUh?=
LP-1 NUfDeoRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTVwNEGyPVEh|ryP M1zWbHNCVkeHUh?=
NCI-SNU-16 Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LLdWlEPTB;NT62OFA4PCEQvF2= MWTTRW5ITVJ?
LU-65 NFLuR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWzbY4yUUN3ME21Mlc3Ozd|IN88US=> M4fpWHNCVkeHUh?=
CW-2 NFzoVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\OPWlEPTB;NT64OVk2QSEQvF2= NE\md2FUSU6JRWK=
WSU-NHL NH7TcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\IPWlEPTB;NT65OVE4PCEQvF2= NYizPZUyW0GQR1XS
IST-MES1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TkT2lEPTB;NT65OVQ1OyEQvF2= NV7ReIFRW0GQR1XS
U-266 M4CweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jZdGlEPTB;NT65PFIxOiEQvF2= NFPjfppUSU6JRWK=
TALL-1 NXnjXIM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjVTJU6UUN3ME22MlE1Pjh6IN88US=> MlXUV2FPT0WU
Calu-6 M3zmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fRXmlEPTB;Nj6xOVMyPiEQvF2= NHG3UG1USU6JRWK=
MMAC-SF NITnbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTZwMUi1OVYh|ryP MYHTRW5ITVJ?
NCI-H82 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnCU4xsUUN3ME22MlIxPDh7IN88US=> NF33ZlVUSU6JRWK=
RS4-11 NHvzb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zjdGlEPTB;Nj6yOVg6PyEQvF2= NVz6NIdTW0GQR1XS
SNU-C2B MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PGZmlEPTB;Nj60NFk3QSEQvF2= MX;TRW5ITVJ?
BOKU MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PYXmlEPTB;Nj60O|U6PyEQvF2= NFfHVnlUSU6JRWK=
C8166 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTZwNUW5NVIh|ryP NV32WlU5W0GQR1XS
D-247MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITISGVKSzVyPUeuNFQ{PDdizszN MnTWV2FPT0WU
EW-18 NE\5TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULWR3BVUUN3ME23MlA4Ojl{IN88US=> NUiyT3NlW0GQR1XS
KG-1 NXzpRll4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7NcmhKSzVyPUeuOlI4OzhizszN M2nxWXNCVkeHUh?=
REH NFvxRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLKU4E2UUN3ME23MlY5OTB7IN88US=> NH7DbJZUSU6JRWK=
U-698-M M1XVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[wVGlEPTB;Nz64OFMyPSEQvF2= NWLNbWt{W0GQR1XS
KP-N-RT-BM-1 NGHRNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7XTWM2OD15LkmzNFI6KM7:TR?= NUD2fZAzW0GQR1XS
MS-1 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXiRpluUUN3ME23Mlk3ODRzIN88US=> NVvVWIR6W0GQR1XS
SNU-C1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTdwOUixPVIh|ryP NH3OfVhUSU6JRWK=
SK-MM-2 NVLr[WVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L6T2lEPTB;OD6yOlA3PSEQvF2= M3nGW3NCVkeHUh?=
LAN-6 M3LTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDDTWM2OD16LkOwNFAyKM7:TR?= M4L3cXNCVkeHUh?=
NEC8 NEXBOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnaOGJKSzVyPUiuN|A3QTFizszN MoH6V2FPT0WU
NCI-H1770 MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRThwM{iwNFIh|ryP MoG3V2FPT0WU
D-336MG M1KxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDFTWM2OD16LkSwNVE3KM7:TR?= NID0d5RUSU6JRWK=
COLO-829 NV\v[JhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfvO4dKSzVyPUiuOFg5PzlizszN MXXTRW5ITVJ?
LS-513 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRThwNUm1PVkh|ryP M4S5SHNCVkeHUh?=
YT NGjzcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP0fo9KSzVyPUiuOlI1OjdizszN M{PiWXNCVkeHUh?=
EW-24 NHXUTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHBTWM2OD16Lke2OVQh|ryP NGX2UpFUSU6JRWK=
IST-SL1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7HTWM2OD16Lki2OVQ{KM7:TR?= M2G4[XNCVkeHUh?=
CA46 M37V[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULBOZkxUUN3ME24Mlk2ODl6IN88US=> NGfRdZpUSU6JRWK=
NCI-H1838 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvzTWM2OD16Lkm4OlAzKM7:TR?= NVzYRohMW0GQR1XS
NCI-H719 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmriTWM2OD17LkK1Nlc6KM7:TR?= NIjOT5dUSU6JRWK=
HCE-T M2nV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13rXWlEPTB;OT6zNFg2OSEQvF2= M3TDTXNCVkeHUh?=
A498 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq5TWM2OD17LkO2NVI1KM7:TR?= MVPTRW5ITVJ?
LB831-BLC NFj6ZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL2fIVKSzVyPUmuO|Y2OjFizszN NXzUSJhjW0GQR1XS
SKM-1 M{XGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVizfHlGUUN3ME25Mlg2QTZ|IN88US=> NH7SV4RUSU6JRWK=
THP-1 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTlwOU[5NVgh|ryP MYfTRW5ITVJ?
SHP-77 NEXKTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS2TWM2OD1zMD60NFch|ryP MYHTRW5ITVJ?
EW-3 M3jhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFyLk[yPFkh|ryP MXjTRW5ITVJ?
KY821 MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDndnd{UUN3ME2xNE44PjNizszN M4HmRnNCVkeHUh?=
NCI-SNU-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXSTWM2OD1zMT6wNlE4KM7:TR?= M1q0dHNCVkeHUh?=
HCC2218 NHHRVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\EZ3NZUUN3ME2xNU4{QTh4IN88US=> NHXvN3BUSU6JRWK=
IM-9 M3y2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli4TWM2OD1zMT61NVA3KM7:TR?= MkT4V2FPT0WU
NCI-H889 NUTsW2RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFzLkWzNVMh|ryP M2P3WHNCVkeHUh?=
HDLM-2 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF{LkSxOVkh|ryP NVjBbplqW0GQR1XS
LB2518-MEL NXGwNGJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zlT2lEPTB;MUKuOlgyPSEQvF2= NEe5b3dUSU6JRWK=
NCI-H23 NGLheHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF|LkK0NlUh|ryP M{S4WHNCVkeHUh?=
NB17 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nLeGlEPTB;MUOuOFU4QSEQvF2= NVzkfXhiW0GQR1XS
NCI-H322M M1\6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPRTWM2OD1zND60NFY5KM7:TR?= MorLV2FPT0WU
SUP-T1 M17mO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;TXpVKSzVyPUG0MlQyOyEQvF2= M17iSnNCVkeHUh?=
ES3 NFrncIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnWwTWM2OD1zNT6wO|A{KM7:TR?= M{juNXNCVkeHUh?=
ES5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonLTWM2OD1zNT6wO|g4KM7:TR?= MU\TRW5ITVJ?
NCI-H1650 MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTQTWM2OD1zNT60PVc6KM7:TR?= MU\TRW5ITVJ?
NCI-H226 NFPKVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHl[YVKSzVyPUG1Mlg4PjhizszN NI\IV2JUSU6JRWK=
COR-L88 NVrUV2FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[wZXhTUUN3ME2xOk4{OTRizszN MULTRW5ITVJ?
SCC-15 M3LGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF4LkO4Olkh|ryP MWLTRW5ITVJ?
GOTO MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO2TWM2OD1zNj60O|k{KM7:TR?= MmTlV2FPT0WU
SIMA MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PBdGlEPTB;MU[uOFgxOiEQvF2= MX;TRW5ITVJ?
NCI-H1299 M{LnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFziXFVKSzVyPUG3MlE2QTFizszN M2\jU3NCVkeHUh?=
NCI-H1581 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorRTWM2OD1zNz60NlE6KM7:TR?= M1fnO3NCVkeHUh?=
MHH-NB-11 NVPqTXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPZTWM2OD1zNz65Olg{KM7:TR?= NYXnPYJVW0GQR1XS
MFM-223 NIjnR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF6LkC1N|gh|ryP NEDOSXBUSU6JRWK=
ES7 M3nHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rydGlEPTB;MUiuOVQ{OSEQvF2= M1\uS3NCVkeHUh?=
JVM-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\ybGlEPTB;MUiuO|E4KM7:TR?= NHPRcXdUSU6JRWK=
RL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\ndI03UUN3ME2yNE4{QDhizszN MVvTRW5ITVJ?
EC-GI-10 M1r6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\rWmlEPTB;MkGuNlA1OSEQvF2= MVvTRW5ITVJ?
LNCaP-Clone-FGC NXPCVFhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG1WWVWUUN3ME2yNU43PzZ6IN88US=> NF7kVXRUSU6JRWK=
IMR-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHLRVBWUUN3ME2yNU45PDl2IN88US=> M{fscXNCVkeHUh?=
KP-N-YS MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFroZldKSzVyPUKxMlg4PSEQvF2= NVXqZZRjW0GQR1XS
Mo-T MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof6TWM2OD1{Mj6yNVg2KM7:TR?= NXLlS|RDW0GQR1XS
NCI-H128 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInHNGhKSzVyPUKzMlU5PTNizszN NF;CU5VUSU6JRWK=
RH-1 M3PRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTjTWM2OD1{Mz63PFY3KM7:TR?= NV\pRW5DW0GQR1XS
NCI-H2171 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPTUYIzUUN3ME2yOE4zPDh3IN88US=> M4nvOnNCVkeHUh?=
RPMI-8866 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ4Lke0NkDPxE1? M136[HNCVkeHUh?=
SK-N-FI M2XQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrIV3NzUUN3ME2yO{4{QDFzIN88US=> NYnlVWdLW0GQR1XS
LOXIMVI MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D6NGlEPTB;MkeuPFA2OSEQvF2= NF7mPZlUSU6JRWK=
P31-FUJ MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLTV4xyUUN3ME2zNU42Ozd2IN88US=> MWrTRW5ITVJ?
KMS-12-PE M3m5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mki1TWM2OD12OT61N|AzKM7:TR?= MWfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-mTOR(S2448)/mTOR; 

PubMed: 23991038     


MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.

23991038
Growth inhibition assay
Cell proliferation; 

PubMed: 30393233     


(A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.

30393233
Histomorphology
Haematoxylin & Eosin; 

PubMed: 28418837     


Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.

28418837
Immunofluorescence
NeuN; 

PubMed: 28418837     


Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown.

p62/Beclin; 

PubMed: 28819214     


(C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody. 

28418837 28819214
ELISA
Type III collagen/Fibronectin; 

PubMed: 23364979     


(A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.

23364979
体内研究 在体内,Rapamycin 处理,特定阻断mTOR下游靶点,如p70S6K磷酸化和激活,和PHAS-1/4E-BP1导致的eIF4E抑制释放, 完全阻断跖肌重量和纤维尺寸的肥厚增高。[3] 短期Rapamycin处理,即使按最低剂量0.16 mg/kg处理, 强抑制p70S6K活性, 与提高的肿瘤细胞死亡和Eker肾脏肿瘤坏死相关。[4] Rapamycin作用于CT-26移植瘤模型,通过降低VEGF产量,及阻断VEGF诱导的内皮细胞信号,而抑制转移性肿瘤生长和血管新生。[5] Rapamycin每天按4 mg/kg剂量处理C6移植瘤,显著降低肿瘤生长,和肿瘤血管通透性。[7]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

mTOR激酶免疫印迹法测定:

HEK293细胞按每孔2-2.5×105个细胞接种在12孔板上,DMEM培养基上血清饥饿处理24小时。使用浓度不断增加的Rapamycin(0.05-50 nM)在 37oC下处理细胞15分钟。加入血清,终浓度为20%,在37oC下处理30分钟。细胞溶解,使用SDS-PAGE分离细胞裂解液。再溶解的蛋白转移到聚偏(二)氟乙烯膜上,使用抗p70 S6激酶Thr-389的磷酸化的一抗进行免疫印迹。使用ImageQuant 和KaleidaGraph分析数据。
细胞实验:

[6]

+ 展开
  • Cell lines: U87-MG, T98G, 和 U373-MG
  • Concentrations: 溶于DMSO,终浓度为~25 μM
  • Incubation Time: 72 小时
  • Method:

    使用不同浓度Rapamycin处理细胞72小时。为了测量细胞活力,通过胰蛋白酶化收集细胞,使用台酚蓝染色,计数每孔的存活细胞数。为了测定细胞周期, 使细胞胰蛋白酶化,与70%乙醇混合, 使用碘化丙啶染色。使用FACScan流式细胞仪和CellQuest软件分析样本DNA含量。为了测定凋亡, 细胞染色,通过末端脱氧核苷酸转移酶调节的dUTP缺口末端标记法(TUNEL)技术,使用一个ApopTag凋亡检测试剂盒对细胞进行染色。为了测定酸性囊泡细胞器(AVO)的进展,使用吖啶橙(1 μg/mL)对细胞进行染色15分钟,使用荧光显微镜检测。为了量化AVOs的进展,使用吖啶橙(1 μg/mL) 对细胞进行染色15分钟, 然后使用胰蛋白酶-EDTA使其从实验板上移除,最后使用FACScan流式细胞仪和CellQuest 软件分析。为了分析自噬过程,细胞和0.05 mM丹(磺)酰戊二胺(MDC)在37oC下温育10分钟,然后在荧光显微镜下观察。


    (Only for Reference)
动物实验:

[7]

+ 展开
  • Animal Models: 皮下接种表达VEGF-A的C6大鼠胶质瘤细胞的无胸腺Nu/Nu小鼠
  • Formulation: 溶于溶剂溶液(0.2% 羧甲基纤维素和0.25% Tween-80,溶于无菌水)
  • Dosages: ~4 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 914.18
化学式

C51H79NO13

CAS号 53123-88-9
稳定性 powder
in solvent
别名 AY 22989,NSC-2260804

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03866681 Not yet recruiting Paroxysmal Nocturnal Hemoglobinuria Peking Union Medical College Hospital April 1 2019 Phase 4
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03877809 Not yet recruiting Beta-Thalassemia Rare Partners srl Impresa Sociale|Università degli Studi di Ferrara April 1 2019 Phase 2
NCT03866681 Not yet recruiting Paroxysmal Nocturnal Hemoglobinuria Peking Union Medical College Hospital April 1 2019 Phase 4
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03877809 Not yet recruiting Beta-Thalassemia Rare Partners srl Impresa Sociale|Università degli Studi di Ferrara April 1 2019 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

相关mTOR产品

Tags: 购买Rapamycin (Sirolimus) | Rapamycin (Sirolimus)供应商 | 采购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)价格 | Rapamycin (Sirolimus)生产 | 订购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID